Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Flubbing the FOBs Opportunity: Follow-on Biologics Winners & Losers

This article was originally published in RPM Report

Executive Summary

An abbreviated pathway for follow-on biologics just missed getting tacked onto the FDA user fee/drug reform legislation. It will be years before proponents get another shot at creating an abbreviated approval pathway for the biotech copycats. So who won and who lost?

You may also be interested in...



In Brave New World of Follow-On Biologics, Can't We Do Better Than 1984?

Congress has moved into the final horse-trading phase of policy development regarding incentives for innovators and biosimilar product developers. The main question on Capitol Hill is what compromise can generate enough support to survive the political process. Jeffrey MOe, a Duke business school professor with experience developing incentives for drug development policy, suggest Congress should reflect before forging its political decision.

Predicting Health Reform: A Quick Guide To What Will Be In-and What Won't

The health care reform debate is entering the critical phase. Here are our predictions for where the legislation will end up.

Predicting Health Reform: A Quick Guide To What Will Be In-and What Won't

The health care reform debate is entering the critical phase. Here are our predictions for where the legislation will end up.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM014079

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel